There exist a close relationship between mutations of KRAS and MAPK1 and the resistance of NSCLC to EGFR-TKI targeted drugs such as Gefitinib and Erlotinib, which can cause sustained activation of the EGFR signaling pathway and accelerate tumor cell proliferation (Zer et al., 2016). Here, KRAS is linked to neoplasm.